文献速递乳腺癌

SOLAR-1 试验中阿培利司联合氟维司群应答的基因组决定因素

Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial.
PubMed 文献 · Ann Oncol · 2026-04-11

该回顾性分析对 SOLAR-1 试验中 398 例患者(237 例 PIK3CA 变异、161 例野生型)进行组织二代测序,在 PIK3CA 变异队列中分析无进展生存期(PFS)相关因素。结果显示,阿培利司联合氟维司群较安慰剂联合氟维司群显著延长 PFS(11.01 对 5.55 个月,P=0.0004),低肿瘤突变负荷及 FGFR1/FGFR2 变异者获益更大,而 MYC 或 RAD21 变异者获益有限。

要点

  • PIK3CA 变异队列中阿培利司联合氟维司群中位 PFS 为 11.01 个月,安慰剂联合氟维司群为 5.55 个月(P=0.0004)。
  • 低肿瘤突变负荷及 FGFR1/FGFR2 变异患者从阿培利司联合氟维司群获得更大 PFS 获益。
  • MYC 或 RAD21 变异患者从阿培利司联合氟维司群获得的 PFS 获益有限。

核心结论

  • 阿培利司联合氟维司群对 PIK3CA 变异的 HR 阳性、HER2 阴性晚期乳腺癌患者具有临床获益,且不受多种伴随变异影响。

研究设计与样本

  • SOLAR-1 试验的回顾性分析,对 398 例患者(237 例 PIK3CA 变异、161 例 PIK3CA 野生型)进行组织二代测序。
  • 在 PIK3CA 变异队列中进行 PFS 相关性分析,并采用 Cox 和多任务机器学习模型识别影响因素。

主要发现

  • PIK3CA 变异与野生型肿瘤具有不同的基因组图谱。
  • PIK3CA 变异队列中,阿培利司联合氟维司群组中位 PFS 为 11.01 个月,安慰剂联合氟维司群组为 5.55 个月(P=0.0004)。
  • 最低肿瘤突变负荷四分位组患者中,阿培利司联合氟维司群对比安慰剂联合氟维司群的中位 PFS 为 18.5 对 3.22 个月(HR 0.38,95%CI 0.21-0.68)。
  • FGFR1 变异患者中位 PFS 为 12.71 对 3.75 个月(HR 0.38,95%CI 0.17-0.81,P=0.32);FGFR2 变异患者为 9.63 对 2.78 个月(HR 0.31,95%CI 0.1-0.94,P=0.29)。
  • MYC 或 RAD21 变异患者从阿培利司联合氟维司群获得的 PFS 获益有限。

关键数值与推荐

  • Cox 和多任务机器学习模型识别出较低 ECOG 体能状态、既往 CDK4/6 抑制剂治疗以及 PTEN 或 TP53 变异是 PIK3CA 变异队列中 PFS 的最不利因素。

临床怎么用

  • 对于 PIK3CA 变异的 HR 阳性、HER2 阴性晚期乳腺癌患者,阿培利司联合氟维司群可作为治疗选择,尤其适用于低肿瘤突变负荷或 FGFR1/FGFR2 变异者。
  • 临床决策时需综合考虑 ECOG 体能状态、既往 CDK4/6 抑制剂治疗史以及 PTEN、TP53、MYC 或 RAD21 等伴随变异对 PFS 的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Approximately 40% of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) have PIK3CA alterations, which contributes to endocrine therapy resistance. Alpelisib, an α-selective phosphatidylinositol 3-kinase inhibitor and degrader, given in combination with fulvestrant, is approved for the treatment of PIK3CA-mutated, HR-positive, HER2-negative ABC, based on the results of the SOLAR-1 trial (NCT02437318). Aside from PIK3CA, other gene alterations are associated with poor prognosis and limited response to treatment in this patient population. PATIENTS AND METHODS: In this retrospective analysis, we carried out tissue-based next-generation sequencing of 398 patients (237 PIK3CA-altered, 161 PIK3CA-wild type) from SOLAR-1. Progression-free survival (PFS) correlative analysis was carried out in the PIK3CA-altered cohort. RESULTS: PIK3CA-altered and PIK3CA-wild type tumors had distinct genomic profiles. In the PIK3CA-altered cohort, patients who received alpelisib plus fulvestrant had a median PFS of 11.01 months versus 5.55 months for those receiving placebo plus fulvestrant (P = 0.0004). Patients in the lowest tumor mutational burden quartile as well as those with FGFR1 or FGFR2 alterations derived greater PFS benefit from alpelisib plus fulvestrant versus placebo plus fulvestrant [18.5 versus 3.22 months: hazard ratio (HR) 0.38, 95% confidence interval (CI) 0.21-0.68; FGFR1 12.71 versus 3.75 months: HR 0.38, 95% CI 0.17-0.81, P = 0.32; FGFR2 9.63 versus 2.78 months: HR 0.31, 95% CI 0.1-0.94, P = 0.29]; patients with MYC or RAD21 alterations derived limited PFS benefit. Cox and multitask machine learning models identified lower Eastern Cooperative Oncology Group performance status, prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) treatment, and PTEN or TP53 alterations among the most deleterious factors for PFS in the PIK3CA-altered cohort. CONCLUSIONS: Alpelisib plus fulvestrant provides clinical benefit for patients with PIK3CA-altered, HR-positive, HER2-negative ABC across a range of concomitant alterations, including those previously implicated in endocrine therapy or CDK4/6i resistance. Machine learning models can identify factors including gene mutations that influenced PFS.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Juric D, Rugo HS, Reising A, et al. Genomic determinants of response to alpelisib plus fulvestrant in the SOLAR-1 trial. Ann Oncol. 2026. PMID: 41967638. doi:10.1016/j.annonc.2026.04.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。